Literature DB >> 11286727

A symbiotic concept of autoimmunity and tumour immunity: lessons from vitiligo.

P K Das1, R M van den Wijngaard, A Wankowicz-Kalinska, I C Le Poole.   

Abstract

Vitiligo is a skin disease in which melanocytes (MCs) are eradicated from lesional epidermis, resulting in disfiguring loss of pigment. MCs are destroyed by MC-reactive T cells, as well as other non-immune and immune components. Similarities exist between the autoimmunity observed in vitiligo and the tumour immunity observed in melanoma immuno-surveillance. An analysis of these mechanisms might lead to the development of new therapies for both vitiligo and melanoma.

Entities:  

Mesh：

Year:  2001        PMID： 11286727     DOI： 10.1016/s1471-4906(00)01844-5

Source DB:  PubMed          Journal:  Trends Immunol        ISSN： 1471-4906            Impact factor:   16.687


  20 in total

Review 1.  Genetics of Vitiligo.

Authors:  Richard A Spritz; Genevieve H L Andersen
Journal:  Dermatol Clin       Date:  2017-04       Impact factor: 3.478

2.  Update on the genetics characterization of vitiligo.

Authors:  Hani A Al-Shobaili
Journal:  Int J Health Sci (Qassim)       Date:  2011-07

Review 3.  Therapeutic implications of autoimmune vitiligo T cells.

Authors:  Kepa Oyarbide-Valencia; Jasper G van den Boorn; Cecele J Denman; Mingli Li; Jeremy M Carlson; Claudia Hernandez; Michael I Nishimura; Pranab K Das; Rosalie M Luiten; I Caroline Le Poole
Journal:  Autoimmun Rev       Date:  2006-05-06       Impact factor: 9.754

4.  HSP70i is a critical component of the immune response leading to vitiligo.

Authors:  Jeffrey A Mosenson; Andrew Zloza; Jared Klarquist; Allison J Barfuss; Jose A Guevara-Patino; I Caroline Le Poole
Journal:  Pigment Cell Melanoma Res       Date:  2011-11-14       Impact factor: 4.693

5.  Evaluation of NLRP1 gene polymorphisms in Vogt-Koyanagi-Harada disease.

Authors:  Yukihiro Horie; Wataru Saito; Nobuyoshi Kitaichi; Toshie Miura; Susumu Ishida; Shigeaki Ohno
Journal:  Jpn J Ophthalmol       Date:  2011-02-18       Impact factor: 2.447

6.  Immune responses in a mouse model of vitiligo with spontaneous epidermal de- and repigmentation.

Authors:  Jonathan M Eby; Hee-Kap Kang; Jared Klarquist; Shilpak Chatterjee; Jeffrey A Mosenson; Michael I Nishimura; Elizabeth Garrett-Mayer; B Jack Longley; Victor H Engelhard; Shikhar Mehrotra; I Caroline Le Poole
Journal:  Pigment Cell Melanoma Res       Date:  2014-07-21       Impact factor: 4.693

7.  CTLA-4 A49G gene polymorphism is not associated with vitiligo in South Indian population.

Authors:  Farha Deeba; Rabbani Syed; Jariya Quareen; M A Waheed; Kaiser Jamil; Hanmanth Rao
Journal:  Indian J Dermatol       Date:  2010       Impact factor: 1.494

8.  Mutant HSP70 reverses autoimmune depigmentation in vitiligo.

Authors:  Jeffrey A Mosenson; Andrew Zloza; John D Nieland; Elizabeth Garrett-Mayer; Jonathan M Eby; Erica J Huelsmann; Previn Kumar; Cecele J Denman; Andrew T Lacek; Frederick J Kohlhapp; Ahmad Alamiri; Tasha Hughes; Steven D Bines; Howard L Kaufman; Andreas Overbeck; Shikhar Mehrotra; Claudia Hernandez; Michael I Nishimura; Jose A Guevara-Patino; I Caroline Le Poole
Journal:  Sci Transl Med       Date:  2013-02-27       Impact factor: 17.956

9.  HSP70i accelerates depigmentation in a mouse model of autoimmune vitiligo.

Authors:  Cecele J Denman; James McCracken; Vidhya Hariharan; Jared Klarquist; Kepa Oyarbide-Valencia; José A Guevara-Patiño; I Caroline Le Poole
Journal:  J Invest Dermatol       Date:  2008-03-13       Impact factor: 8.551

10.  Vogt-Koyanagi-Harada syndrome associated with cutaneous malignant melanoma: an 11-year follow-up.

Authors:  Sabine Aisenbrey; Christoph Lüke; Helen D Ayertey; Salvatore Grisanti; Andreas Perniok; Richard Brunner
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-11-14       Impact factor: 3.117
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.